# MetLife Inc. (MET) fundamentals

Data as of 2026-11-04. NYSE, United States. Sector: Financial Services / Insurance. Price $100.67, market value $64.0 billion.

## Valuation
- **P/E (trailing): 19.3×** (5-yr avg 16.2×, 3-yr avg 21.2×). MetLife Inc. trades at 19.3× trailing earnings, close to its own five-year average of 16.2×. The Financial Services median in the September 2026 study was 13.1×. Forward P/E is 9.0×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 3.0×**. Each dollar of revenue is priced at 3.0×.
- **Price / book: 2.3×**. The shares trade at 2.3× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 6.3×**. Enterprise value is 6.3× operating earnings before depreciation, the multiple that ignores how the company is financed; below 8× is inexpensive for most sectors.
- **Earnings yield: 5.2%**. The inverse of the P/E: 5.2% of the price is earned each year.

## Profitability
- **Operating margin: 31.1%**. 31.1% of revenue is left after running the business, an exceptional level.
- **Net margin: 138.7%**. 138.7% of each dollar of sales reaches the bottom line.
- **Return on equity: 11.9%**. 11.9% on shareholders' equity is solid.
- **Return on invested capital: 77.2%**. Return on all capital, debt included, is 77.2%: comfortably above what that capital costs.
- **Return on assets: 0.5%**. Each dollar of assets produces 0.5% of profit; low single digits are normal for banks and insurers.

## Growth
- **Revenue growth (1 yr): 8.5%** (3-yr 4.9%/yr, 5-yr 12.5%/yr). Revenue grew 8.5% over the last year, against 12.5% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -20.7%** (3-yr -9.2%/yr, 5-yr -3.7%/yr). Earnings per share fell 20.7%, slower than revenue, so margins compressed.

## Financial health
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.
- **Cash and short-term investments: $22.0 billion**. Leverage ratios are shown differently for banks and insurers, whose balance sheets are built on deposits and reserves; use return on equity and the regulatory capital in the filings instead.

## Dividends
- **Dividend yield: 2.35%** ($2.29 per share, trailing). MetLife Inc. yields 2.35%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 45%**. 45% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 26**. 26 straight years of increases (the data covers 26 years, so this may be longer): a record very few companies hold.
- **Dividend growth (5 yr): 4.3%/yr** (1-yr 4.4%). The dividend has grown 4.3% a year over five years.
- **Shareholder yield: 6.2%**. Dividends plus net buybacks return 6.2% of the market value a year.

## Analyst view
- **Analyst consensus: buy** (16 analysts). 16 analysts cover MetLife Inc.; the consensus is buy, with an average price target of $107.63 (+7% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 29.3%** (YTD 29.8%, 3-mo 4.8%). The shares are up 29.3% over twelve months including dividends.
- **From 52-week high: -2.9%** (49.5% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 56**. An RSI of 56 is neutral.
- **Beta (1 yr): 0.64** (volatility 24%). Beta of 0.64 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=MET · Page: https://foliofundamentals.com/stocks/met

Not investment advice.